5 results about "Tail vein" patented technology

This utility model relates to a simple experimental mouse fixation and tail vein injection device, including a fixation platform, a transparent isolation cover, and a tail fixation component. The transparent isolation cover is used to cover the experimental mouse on the fixation platform. An isolation cover notch is formed at the edge of the open end of the transparent isolation cover, through which the tail of the experimental mouse protrudes. The tail fixation component is used to fix the protruding tail of the experimental mouse on the fixation platform. This utility model combines experimental mouse fixation, tail fixation, and visual monitoring, achieving a dual improvement in drug administration accuracy and simplified experimental operation. It can be operated by a single person and is suitable for precise drug delivery and real-time image monitoring in small animal experiments, possessing high practical value and promising prospects for widespread application.

This utility model discloses an auxiliary device for tail vein injection in medical experimental mice. Relating to the technical field of medical experimental equipment, the device includes a base with a fixing frame installed near the edge of the top. A fixing component is provided on the top of the base, and an observation component is provided on one outer wall of the fixing frame. The fixing component includes a lower fixing plate and an upper fixing plate, with the upper fixing plate positioned above the lower fixing plate. This auxiliary device for tail vein injection in medical experimental mice allows the upper fixing plate to move upward a certain distance by pulling a lever, overcoming the spring's thrust, and completely separating the upper and lower arc-shaped plates. The mouse is then placed on the lower arc-shaped plate. Releasing the lever causes the upper arc-shaped plate to move downward under the spring's thrust, thus securing the mouse and effectively avoiding the problem of mice being difficult to stabilize due to their active and restless nature.

This invention discloses a method for constructing a mouse model of non-obese NAFLD in humans under normal dietary conditions. The method involves injecting adeno-associated virus (adenovirus) shIDO2-AAV8 into mice via the tail vein to target and silence IDO2 gene expression in the liver, while simultaneously administering a normal diet. The adenovirus shIDO2-AAV8 is obtained by recombining an IDO2-shRNA sequence inserted into an AAV8 vector. This invention, through tail vein injection of adenovirus shIDO2-AAV8 combined with a normal diet, can construct a mouse model simulating non-obese NAFLD in humans. Compared with traditional dietary induction methods and combined induction methods, the dietary conditions are consistent with daily human intake, more closely reflecting the actual pathological situation in humans, and more closely reproducing the pathogenesis environment and physical state of non-obese NAFLD in humans, making the model more clinically valuable.

The application relates to the field of biological medicine, and discloses a medicine for relieving autoimmune prostatitis and application thereof, which comprises an active ingredient and a pharmaceutically acceptable sterile phosphate buffer carrier; the active ingredient is live Lactobacillus johnsonii with a number of BNCC135265 or extracellular vesicles of Lactobacillus johnsonii; the final concentration of live bacteria in the medicine is 1x10 8 to 1x10 10 CFU / mL, which is used for preparing a preparation for intragastric administration; the extracellular vesicles contain 1x10 8 to 5x10 9 particles per unit dosage form, which is used for preparing a preparation for tail vein injection administration. By using the live bacteria with the specific number or the extracellular vesicles thereof, intestinal mucosa colonization can be achieved to block endotoxin into blood, or the extracellular vesicles can be enriched in prostate lesions to inhibit a nuclear factor-kappa B inflammatory signaling pathway, reduce synthesis of proinflammatory cytokines and lymphocyte infiltration, and finally realize relief of autoimmune prostatitis.

The application discloses a kind of methods for constructing deep vein thrombosis mouse model by regulating Pyk2 gene expression.The method comprises the following steps: constructing knockdown or overexpression vector for Pyk2 gene; by tail vein injection, the vector is introduced into mouse in vivo, the in vivo transient regulation of Pyk2 gene is realized; the inferior vena stenosis method is used to induce deep vein thrombosis; the thrombus macroscopic morphology, wet weight, length and histopathology are detected.The application overcomes the limitation of existing gene knockout model, such as congenital, irreversible and systemic deletion, realizes the targeted, temporary and bidirectional flexible regulation of Pyk2 gene in vascular tissue, and the model has high stability and good repeatability.The model can simulate the pathological state under the same expression level of Pyk2, and is suitable for the screening, evaluation and deep vein thrombosis pathogenesis research of antithrombotic drugs.